Phase I single and multiple ascending dose trial of NTa53

Phase I single and multiple ascending dose trial of NTa53, Confirmation of pharmacokinetics and safety of NTa53 in healthy Japanese adult males volunteer for single and repeated dose

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2051210123

Enrollment

Registered

2021-11-24

Start date

2021-11-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic conjunctivitis

Interventions

Administration of NTa53 or placebo and blood sampling

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: - Healthy Japanese male of 20-45 years of age at the time of the informed consent - Judged by the investigator as being eligible at a result of the screening test - Other protocol-specified inclusion criteria may apply

Exclusion criteria

Exclusion criteria: - History of allergy symptoms such as asthma, atopic dermatitis, etc. - Judged by the investigator as being ineligible - Other protocol-specified exclusion criteria may apply

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics and safety	—

Contacts

Public ContactResearch Development

Nitto Medic Co., Ltd.

clinical@nittomedic.co.jp+81-76-455-3541

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026